Investigational drug · Phase 2
TQC2938
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Obstructive Pulmonary Disease, Seasonal Allergic Rhinitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "TQC2938"
First trial start
2025
Mar 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQC2938", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Obstructive Pulmonary Disease
- Seasonal Allergic Rhinitis
Approved drugs for the same conditions: COPD · Allergies (allergic rhinitis) · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "TQC2938" as an intervention, largest first.
- A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingActive, not recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06789289 · 256 participants · Start Mar 17, 2025 · Primary completion Mar 17, 2027
Drug: TQC2938 injection; TQC2938 injection Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Hefei, China; Beijing, China; Chongqing, China · 40 sites in all
- Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic RhinitisPivotal-lookingCompleted
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT07052097 · 136 participants · Start Jul 31, 2025 · Primary completion Sep 12, 2025
Drug: TQC2938 injection; TQC2938 Placebo · For: Seasonal Allergic Rhinitis
Sites: Beijing, China; Lanzhou, China; Cangzhou, China · 30 sites in all
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06449859 · 84 participants (planned) · Start Jun 13, 2023 · Primary completion Nov 2024
Drug: TQC2938 Injection; TQC2938 Placebo · For: Asthma
Sites: Zhengzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Obstructive Pulmonary Disease
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- ItepekimabREGN3500, SAR440340Phase 39 trials
Sanofi · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- VerducatibBI 1291583Phase 34 trials
Boehringer Ingelheim · Bronchiectasis, Chronic Obstructive Pulmonary Disease
- AstegolimabPhase 33 trials
Roche (Genentech) · Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD)
- CM326Phase 33 trials
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Moderate to Severe Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.